Lidocaine (hydrochloride)

CAT:
804-HY-B0185A-01
Size:
500 mg

For Laboratory Research Only. Not for Clinical or Personal Use.

  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Lidocaine (hydrochloride) - image 1

Lidocaine (hydrochloride)

  • UNSPSC Description:

    Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride is an amide derivative and a agent to treat ventricular arrhythmia and an effective tumor-inhibitor[2].
  • Target Antigen:

    Apoptosis; ERK; MEK; NF-κB; Sodium Channel
  • Type:

    Reference compound
  • Related Pathways:

    Apoptosis;MAPK/ERK Pathway;Membrane Transporter/Ion Channel;NF-κB;Stem Cell/Wnt
  • Applications:

    Cancer-Kinase/protease
  • Field of Research:

    Cancer; Cardiovascular Disease
  • Assay Protocol:

    https://www.medchemexpress.com/Lidocaine-hydrochloride.html
  • Purity:

    99.96
  • Solubility:

    DMSO : ≥ 100 mg/mL|H2O : ≥ 100 mg/mL
  • Smiles:

    O=C(NC1=C(C)C=CC=C1C)CN(CC)CC.[H]Cl
  • Molecular Weight:

    270.80
  • References & Citations:

    [1]Cummins TR, et al. Setting up for the block: the mechanism underlying lidocaine's use-dependent inhibition of sodium channels. J Physiol. 2007 Jul 1;582(Pt 1):11.|[2]Sui H, et al. Lidocaine inhibits growth, migration and invasion of gastric carcinoma cells by up-regulation of miR-145. BMC Cancer. 2019 Mar 15;19(1):233.|[3]Li Z, et al. Evaluation of the antinociceptive effects of lidocaine and bupivacaine on the tail nerves of healthy rats. Basic Clin Pharmacol Toxicol. 2013 Jul;113(1):31-6.Eur Spine J. 2022 Sep 24.|J Phys D Appl Phys. 2019 Aug; 52(46).|Cell Rep Methods. 2023 Oct 23;3(10):100599.|Dig Dis Sci. 2021 Jan 12.|Drug Des Devel Ther. 2024 Apr 9:18:1103-1114.|Int Immunopharmacol. 2023 Jan 11;115:109706.|J Neuroinflammation. 2017 Nov 2;14(1):211.|Mol Med Rep. 2022 May;25(5):150.|Nat Methods. 2021 Jul;18(7):788-798.|Neurogastroenterol Motil. 2023 Sep 21;e14677.|PLoS Pathog. 2023 Feb 3;19(2):e1011126.|Stem Cell Res Ther. 2021 Feb 4;12(1):107.|University of Glasgow. School of Cancer Sciences.
  • Shipping Conditions:

    Room Temperature
  • Storage Conditions:

    4°C (Powder, sealed storage, away from moisture and light)
  • Clinical Information:

    Launched
  • CAS Number:

    73-78-9